Cytokinetics (NASDAQ:CYTK) Cut to "Sell" at Wall Street Zen

Key Points

• Wall Street Zen downgraded Cytokinetics to “sell” from “hold,” despite the broader analyst consensus remaining “Moderate Buy,” with 19 buy ratings and an average price target of $105.44.
• Cytokinetics shares opened at $62.65, well below their 52-week high of $88.31. The company reported a quarterly loss of $1.50 per share, though it beat expectations and generated $28.62 million in revenue.
• Recent developments provide both potential upside and caution: Health Canada approved MYQORZO, while company insiders sold roughly $13.3 million of stock over the last quarter.

Cytokinetics (NASDAQ:CYTK - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a report issued on Tuesday, Wall Street Zen reports.

A number of other brokerages also recently issued reports on CYTK. Barclays boosted their price objective on shares of Cytokinetics from $95.00 to $110.00 and gave the company an "overweight" rating in a research report on Thursday, August 13th. Royal Bank Of Canada raised their price objective on shares of Cytokinetics from $112.00 to $113.00 and gave the company an "outperform" rating in a research report on Thursday, October 8th. Citizens Jmp lifted their target price on shares of Cytokinetics from $105.00 to $110.00 and gave the company a "market outperform" rating in a research note on Friday, August 7th. HC Wainwright reaffirmed a "buy" rating and issued a $140.00 target price on shares of Cytokinetics in a report on Monday. Finally, Truist Financial increased their price target on Cytokinetics from $106.00 to $112.00 and gave the stock a "buy" rating in a research note on Monday, August 10th. Nineteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $105.44.

Cytokinetics Price Performance

Shares of NASDAQ:CYTK opened at $62.65 on Tuesday. Cytokinetics has a 1-year low of $54.30 and a 1-year high of $88.31. The business has a fifty day moving average price of $69.88 and a 200-day moving average price of $73.25. The company has a market capitalization of $7.80 billion, a PE ratio of -8.68 and a beta of 0.41.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.63) by $0.13. The company had revenue of $28.62 million during the quarter, compared to analysts' expectations of $17.59 million. During the same period in the prior year, the firm earned ($1.12) EPS. Cytokinetics's revenue for the quarter was down 57.1% compared to the same quarter last year. On average, sell-side analysts anticipate that Cytokinetics will post -5.97 earnings per share for the current fiscal year.

Insider Transactions at Cytokinetics

In other Cytokinetics news, CEO Robert I. Blum sold 97,926 shares of the business's stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $69.33, for a total value of $6,789,209.58. Following the sale, the chief executive officer owned 385,320 shares in the company, valued at $26,714,235.60. The trade was a 20.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director B. Parshall sold 5,000 shares of the business's stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $71.48, for a total transaction of $357,400.00. Following the completion of the sale, the director owned 10,784 shares in the company, valued at approximately $770,840.32. The trade was a 31.68% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 187,926 shares of company stock valued at $13,319,820. 2.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Cytokinetics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CYTK. V Square Quantitative Management LLC lifted its position in Cytokinetics by 71.5% during the third quarter. V Square Quantitative Management LLC now owns 458 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 191 shares during the last quarter. Nvwm LLC increased its holdings in shares of Cytokinetics by 5.2% in the 3rd quarter. Nvwm LLC now owns 9,600 shares of the biopharmaceutical company's stock worth $633,000 after buying an additional 477 shares during the last quarter. Sanders Morris Harris LLC bought a new stake in shares of Cytokinetics in the 3rd quarter worth about $1,549,000. Mirador Capital Partners LP raised its position in shares of Cytokinetics by 3.2% during the 3rd quarter. Mirador Capital Partners LP now owns 208,896 shares of the biopharmaceutical company's stock valued at $13,768,000 after buying an additional 6,526 shares in the last quarter. Finally, GAMMA Investing LLC raised its position in shares of Cytokinetics by 8.6% during the 3rd quarter. GAMMA Investing LLC now owns 2,700 shares of the biopharmaceutical company's stock valued at $178,000 after buying an additional 213 shares in the last quarter.

Cytokinetics News Roundup

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Health Canada authorized MYQORZO for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), giving Cytokinetics another international market in which to commercialize its once-daily cardiac myosin inhibitor. The approval was based on clinical data, including a 24-week trial, and could support future revenue growth and broader adoption. Health Canada approval announcement
• Positive Sentiment: Analyst HC Wainwright reaffirmed its “buy” rating and maintained a $140 price target, implying substantial upside based on the stock’s recent trading level. The firm’s view reflects optimism about MYQORZO’s commercial opportunity and Cytokinetics’ pipeline. HC Wainwright analyst update
• Positive Sentiment: Growing prescriptions, international launches and encouraging clinical data are strengthening the investment case for MYQORZO. Continued adoption could expand the drug’s addressable market and improve Cytokinetics’ longer-term revenue outlook. MYQORZO growth analysis
• Neutral Sentiment: BofA Securities lowered its CYTK price target to $81 from $85 while maintaining a neutral rating. The revised target remains above the recent share price, but the reduction signals more measured expectations than the bullish views from other analysts. BofA Securities price target update
• Negative Sentiment: Cytokinetics granted options covering 60,465 shares and 40,084 restricted stock units to 29 new employees. The awards may modestly increase future share dilution, although they are intended to support hiring and employee retention. Cytokinetics inducement grants announcement

About Cytokinetics

Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering and developing medicines that target muscle function and contractility. The company applies muscle biology and sarcomere science to develop potential treatments for cardiovascular and neuromuscular diseases, including conditions in which impaired muscle performance contributes to disease progression.

Its leading investigational program is aficamten, a selective cardiac myosin inhibitor being developed for hypertrophic cardiomyopathy and other potential cardiovascular indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.